QTTB logo

QTTB Q32 Bio Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$8.34
-0.14 (-1.65%)

Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fus…

Market Cap: $249.57Mwww.q32bio.com

Price

No data yet.

Social Signal Score

49
5d
—
30d
—
60d
50
2 mentions
—
90d
49
5 mentions
—
news: 5

Analyst Ratings

8 analysts
Buyconsensus
Strong Buy 0Buy 4Hold 4Sell 0Strong Sell 0
Avg price target$36.5+337.6%
Low $14Median $35High $66
Current Consensus

Revenue

$0.00
$-14.66M$8.14M$30.94M$53.74M
Sep 2017Sep 2026

Analyst Estimates

FY2025
$-2.81
$-3.00–$-2.61
2 analysts
FY2026
$-1.36
$-1.40–$-1.31
6 analysts
FY2027
$-2.07
$-2.49–$-1.38
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Jodie Pope Morrison
Sector
Healthcare
Industry
Biotechnology
Employees
22
Beta
-0.33
Country
US
Piotroski score
5 / 9 (Middling)
Altman Z-score
16.32
www.q32bio.com